Advertisement
CYTK vs IONS
Which Stock Would AI Choose? Cytokinetics (CYTK) vs. Ionis Pharmaceuticals (IONS) Stock Comparison
Key Takeaways
- IONS boasts a larger market capitalization of approximately $12.1 billion compared to CYTK's $8.1 billion, reflecting greater scale in the biotechnology sector.
- IONS generated $944 million in 2025 revenue, up 34% year-over-year, while CYTK remains largely pre-commercial with focus on its MYQORZO launch.
- CYTK shows recent upward momentum, crossing above its 50-day moving average, contrasting IONS' strong one-year gains of over 140% amid a recent pullback.
- Both stocks feature promising pipelines: CYTK's aficamten for hypertrophic cardiomyopathy (HCM) and IONS' olezarsen with FDA priority review and PDUFA date of June 30, 2026.
- IONS benefits from multiple commercial products like TRYNGOLZA and WAINUA, providing revenue stability over CYTK's development-stage risks.
- Tickeron's AI signals highlight bullish trends for both, but IONS holds a Strong Buy consensus with higher analyst price targets.
Introduction
Biotechnology investors often compare CYTK and IONS due to their focus on innovative therapies targeting cardiovascular and neuromuscular diseases. Cytokinetics develops muscle modulators for conditions like obstructive hypertrophic cardiomyopathy (oHCM), while Ionis pioneers RNA-targeted medicines for rare genetic disorders. This stock comparison analyzes their recent market performance, pipeline progress, and relative positioning in a volatile biotech landscape. Traders seeking momentum plays or income stability, and long-term investors eyeing catalysts, will find value in understanding their contrasts amid broader sector recovery and regulatory milestones.
CYTK Overview and Recent Performance
Cytokinetics, Incorporated (CYTK) is a late-stage biopharmaceutical company specializing in small-molecule muscle activators and inhibitors for debilitating heart and muscle diseases. Its approved product, MYQORZO, an oral cardiac myosin inhibitor, treats symptomatic oHCM, with recent launch progress highlighted at conferences like the Needham Healthcare event. The pipeline includes next-generation candidate aficamten for HCM and heart failure with preserved ejection fraction (HFpEF).
In recent market activity, CYTK shares have exhibited upward momentum, crossing above the 50-day moving average and showing bullish Aroon and momentum signals per AI analysis. Trading around $65 with a market cap of $8.1 billion, the stock has gained over 60% in the past year, driven by pipeline teasers for Phase 3 readouts and upcoming first-quarter earnings. Sentiment has improved on launch execution and reduced cash burn concerns, though volatility persists in the pre-revenue phase.
IONS Overview and Recent Performance
Ionis Pharmaceuticals, Inc. (IONS) is a commercial-stage biotechnology firm leveraging antisense oligonucleotide technology for RNA-targeted therapies across neurology, cardiology, and rare diseases. Key products include TRYNGOLZA for familial chylomicronemia syndrome (FCS), DAWNZERA for hereditary angioedema (HAE), and WAINUA for hereditary transthyretin-mediated amyloidosis polyneuropathy (ATTRv-PN).
Recent performance underscores IONS' resilience, with shares near $73 and a $12.1 billion market cap following 147% one-year returns. Revenue hit $944 million in 2025, up 34%, fueled by product launches, though 2026 guidance of $800-825 million reflects investment in the pipeline. Positive drivers include FDA priority review for olezarsen in severe hypertriglyceridemia (SHTG) and new data on zilganersen for Alexander disease. AI signals show bullish Aroon and RSI uptrends, supporting outperformance versus biotech peers despite short-term pullbacks.
Trending AI Robots
Tickeron's Trending AI Robots page features a curated selection of the platform's top-performing AI trading bots, drawn from hundreds available that trade thousands of tickers across stocks, ETFs, and crypto. Only the most suitable for current market conditions—based on factors like high annualized returns (up to +167%), win rates (50-80%), and profit factors—earn a spot among the top 25 out of 351 bots. These include short-term scalpers (5-60 minutes) on semiconductors like SOXL (+93% annualized, 68% win rate) and swing traders on small caps (+98% annualized, 59% win rate), adapting to volatility in tech, energy, and defense. Diverse strategies suit aggressive growth or risk-managed approaches. Investors can explore these real-time signals via virtual or brokerage agents to enhance portfolio decisions.
Head-to-Head Comparison
CYTK and IONS operate in biotechnology but diverge in models: CYTK emphasizes proprietary small molecules for muscle contractility in niche cardiac indications, remaining development-focused, while IONS employs licensed antisense tech for a broader rare disease portfolio with established royalties and sales.
Growth drivers contrast sharply—CYTK relies on MYQORZO ramp-up and aficamten approvals versus IONS' multi-product revenue and late-stage assets like olezarsen. Recent momentum favors CYTK's short-term uptrend amid biotech rotation, but IONS dominates long-term relative performance with superior scale. Risks include clinical trial failures for both, though IONS mitigates via diversification; CYTK faces higher burn rate pre-commercialization. Sector exposure overlaps in cardio-metabolics, but IONS extends to neurology. Market sentiment tilts toward IONS' profitability path, per analyst targets, over CYTK's higher-beta speculation.
Tickeron AI Verdict
Tickeron's AI currently leans toward IONS in this stock comparison, citing greater trend consistency from revenue growth, pipeline catalysts like the olezarsen PDUFA, and relative stability versus biotech volatility. While CYTK offers momentum upside, IONS' Strong Buy signals and peer outperformance suggest higher probability of positive positioning in coming months.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Buy and IONS is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CYTK’s FA Score shows that 1 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).
- CYTK’s FA Score: 1 green, 4 red.
- IONS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CYTK’s TA Score shows that 5 TA indicator(s) are bullish while IONS’s TA Score has 5 bullish TA indicator(s).
- CYTK’s TA Score: 5 bullish, 4 bearish.
- IONS’s TA Score: 5 bullish, 4 bearish.
Price Growth
CYTK (@Biotechnology) experienced а +6.38% price change this week, while IONS (@Biotechnology) price change was +3.97% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.83%. For the same industry, the average monthly price growth was +1.96%, and the average quarterly price growth was +1945.11%.
Reported Earning Dates
CYTK is expected to report earnings on Jul 30, 2026.
IONS is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Biotechnology (+5.83% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| CYTK | IONS | CYTK / IONS | |
| Capitalization | 10.9B | 12.6B | 87% |
| EBITDA | -704.15M | -217.15M | 324% |
| Gain YTD | 25.921 | -3.944 | -657% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 106M | 1.06B | 10% |
| Total Cash | 819M | 1.92B | 43% |
| Total Debt | 1.29B | 2.04B | 63% |
CYTK | IONS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 59 | 34 | |
SMR RATING 1..100 | 100 | 99 | |
PRICE GROWTH RATING 1..100 | 38 | 44 | |
P/E GROWTH RATING 1..100 | 1 | 62 | |
SEASONALITY SCORE 1..100 | 50 | 1 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CYTK's Valuation (100) in the Biotechnology industry is in the same range as IONS (100). This means that CYTK’s stock grew similarly to IONS’s over the last 12 months.
IONS's Profit vs Risk Rating (34) in the Biotechnology industry is in the same range as CYTK (59). This means that IONS’s stock grew similarly to CYTK’s over the last 12 months.
IONS's SMR Rating (99) in the Biotechnology industry is in the same range as CYTK (100). This means that IONS’s stock grew similarly to CYTK’s over the last 12 months.
CYTK's Price Growth Rating (38) in the Biotechnology industry is in the same range as IONS (44). This means that CYTK’s stock grew similarly to IONS’s over the last 12 months.
CYTK's P/E Growth Rating (1) in the Biotechnology industry is somewhat better than the same rating for IONS (62). This means that CYTK’s stock grew somewhat faster than IONS’s over the last 12 months.
| CYTK | IONS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 83% | N/A |
| Stochastic ODDS (%) | 1 day ago 87% | 1 day ago 72% |
| Momentum ODDS (%) | 1 day ago 76% | 1 day ago 69% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 75% | 1 day ago 71% |
| TrendMonth ODDS (%) | 1 day ago 78% | 1 day ago 74% |
| Advances ODDS (%) | 1 day ago 76% | 1 day ago 66% |
| Declines ODDS (%) | 16 days ago 76% | 16 days ago 63% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 76% |
| Aroon ODDS (%) | N/A | N/A |
Advertisement
IONS and
Correlation & Price change
A.I.dvisor indicates that over the last year, IONS has been loosely correlated with CYTK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then CYTK could also see price increases.
| Ticker / NAME | Correlation To IONS | 1D Price Change % | ||
|---|---|---|---|---|
| IONS | 100% | +0.13% | ||
| CYTK - IONS | 66% Loosely correlated | +1.06% | ||
| MLYS - IONS | 64% Loosely correlated | +0.91% | ||
| ARWR - IONS | 47% Loosely correlated | -2.60% | ||
| MNKD - IONS | 47% Loosely correlated | +0.77% | ||
| AXON - IONS | 43% Loosely correlated | +5.61% | ||
More | ||||